Candriam Luxembourg S.C.A. reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,875 shares of the company’s stock after selling 1,201 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Teva Pharmaceutical Industries Limited were worth $395,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Rothschild Investment Corp IL raised its position in Teva Pharmaceutical Industries Limited by 1.9% in the first quarter. Rothschild Investment Corp IL now owns 8,870 shares of the company’s stock worth $285,000 after buying an additional 166 shares during the period. Butensky & Cohen Financial Security Inc. raised its position in Teva Pharmaceutical Industries Limited by 5.5% in the first quarter. Butensky & Cohen Financial Security Inc. now owns 35,351 shares of the company’s stock worth $1,134,000 after buying an additional 1,834 shares during the period. Coastline Trust Co raised its position in Teva Pharmaceutical Industries Limited by 3.6% in the first quarter. Coastline Trust Co now owns 29,990 shares of the company’s stock worth $962,000 after buying an additional 1,040 shares during the period. Greylin Investment Mangement Inc. raised its position in Teva Pharmaceutical Industries Limited by 131.8% in the first quarter. Greylin Investment Mangement Inc. now owns 215,195 shares of the company’s stock worth $6,906,000 after buying an additional 122,340 shares during the period. Finally, DnB Asset Management AS raised its position in Teva Pharmaceutical Industries Limited by 340.7% in the first quarter. DnB Asset Management AS now owns 73,600 shares of the company’s stock worth $2,362,000 after buying an additional 56,900 shares during the period. Hedge funds and other institutional investors own 56.04% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.97 on Wednesday. Teva Pharmaceutical Industries Limited has a 52 week low of $16.81 and a 52 week high of $53.96. The company has a 50-day moving average of $28.78 and a 200 day moving average of $31.30. The firm’s market cap is $18.26 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the business earned $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.89%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -18.95%.

COPYRIGHT VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/16/candriam-luxembourg-s-c-a-has-395000-position-in-teva-pharmaceutical-industries-limited-teva.html.

A number of research firms recently weighed in on TEVA. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price objective on the stock. in a research report on Tuesday, July 4th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $33.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. Three equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and a consensus target price of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.